Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 551-571 , August 2008

Nutrition, metabolic factors and cancer risk

  • Rudolf Kaaks, PhD (Division Head)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49 6221 422200; Fax: +49 6221 422203.

References 

  1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians. 2005 Mar;55(2):74–108
  2. World Cancer Research Fund/American Institute for Cancer Research . Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington DC: AICR; 2007;
  3. International Agency for Research on Cancer (WHO) . IARC handbooks of cancer prevention. Weight control and physical activity. Lyon: IARC Press; 2002;
  4. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature Reviews. Cancer. 2004 Aug;4(8):579–591
  5. Larsson SC, Wolk A. Obesity and risk of non-Hodgkin's lymphoma: a meta-analysis. International Journal of Cancer. 2007 Oct 1;121(7):1564–1570
  6. Key TJ, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. European Journal of Cancer & Clinical Oncology. 1988 Jan;24(1):29–43
  7. Boyd DB. Insulin and cancer. Integrative Cancer Therapies. 2003 Dec;2(4):315–329
  8. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. Journal of the National Cancer Institute. 2000 Sep 20;92(18):1472–1489
  9. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002 Dec 19;420(6917):860–867
  10. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. The Journal of Clinical Endocrinology and Metabolism. 2004 Jun;89(6):2548–2556
  11. McTiernan A. Mechanisms linking physical activity with cancer. Nature Reviews. Cancer. 2008 Mar;8(3):205–211
  12. Bassuk SS, Manson JE. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. Journal of Applied Physiology. 2005 Sep;99(3):1193–1204
  13. van Baak MA, Borghouts LB. Relationships with physical activity. Nutrition Reviews. 2000 Mar;58(3 Pt 2):S16–S18
  14. Pan DA, Lillioja S, Kriketos AD, et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997 Jun;46(6):983–988
  15. Perseghin G, Price TB, Petersen KF, et al. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. The New England Journal of Medicine. 1996 Oct 31;335(18):1357–1362
  16. McAuley K, Mann J. Thematic review series: patient-oriented research. Nutritional determinants of insulin resistance. Journal of Lipid Research. 2006 Aug;47(8):1668–1676
  17. Storlien LH, Jenkins AB, Chisholm DJ, et al. Influence of dietary fat composition on development of insulin resistance in rats. Relationship to muscle triglyceride and omega-3 fatty acids in muscle phospholipid. Diabetes. 1991 Feb;40(2):280–289
  18. Vessby B, Unsitupa M, Hermansen K, et al. Substituting dietary saturated for monounsaturated fat impairs insulin sensitivity in healthy men and women: The KANWU Study. Diabetologia. 2001 Mar;44(3):312–319
  19. Perez-Jimenez F, Lopez-Miranda J, Pinillos MD, et al. A Mediterranean and a high-carbohydrate diet improve glucose metabolism in healthy young persons. Diabetologia. 2001 Nov;44(11):2038–2043
  20. Wolever TM, Jenkins DJ, Jenkins AL, et al. The glycemic index: methodology and clinical implications. The American Journal of Clinical Nutrition. 1991 Nov;54(5):846–854
  21. Ludwig DS. The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. The Journal of the American Medical Association. 2002 May 8;287(18):2414–2423
  22. Barclay AW, Petocz P, Millan-Price J, et al. Glycemic index, glycemic load, and chronic disease risk–a meta-analysis of observational studies. The American Journal of Clinical Nutrition. 2008 Mar;87(3):627–637
  23. Livesey G, Taylor R, Hulshof T, et al. Glycemic response and health–a systematic review and meta-analysis: relations between dietary glycemic properties and health outcomes. The American Journal of Clinical Nutrition. 2008 Jan;87(1):258S–268S
  24. Report of a joint WHO/FAO expert consultation . Diet, nutrition and the prevention of chronic diseases. Geneva: World Health Organization; 2003;
  25. Pereira MA, Jacobs DR, Van HL, et al. Dairy consumption, obesity, and the insulin resistance syndrome in young adults: the CARDIA Study. The Journal of the American Medical Association. 2002 Apr 24;287(16):2081–2089
  26. Ma B, Lawson AB, Liese AD, et al. Dairy, magnesium, and calcium intake in relation to insulin sensitivity: approaches to modeling a dose-dependent association. American Journal of Epidemiology. 2006 Sep 1;164(5):449–458
  27. Giovannucci E. Insulin and colon cancer. Cancer Causes & Control. 1995 Mar;6(2):164–179
  28. Keown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk?. Cancer Epidemiology, Biomarkers & Prevention. 1994 Dec;3(8):687–695
  29. Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link?. Cancer Causes & Control. 1996 Nov;7(6):605–625
  30. Rutanen EM, Pekonen F, Nyman T, et al. Insulin-like growth factors and their binding proteins in benign and malignant uterine diseases. Growth Regulation. 1993 Mar;3(1):74–77
  31. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiology, Biomarkers & Prevention. 2002 Dec;11(12):1531–1543
  32. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature Reviews. Cancer. 2002 Jul;2(7):489–501
  33. Cully M, You H, Levine AJ, et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumourigenesis. Nature Reviews. Cancer. 2006 Mar;6(3):184–192
  34. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Archives of Physiology and Biochemistry. 2008 Feb;114(1):63–70
  35. Cust AE, Allen NE, Rinaldi S, et al. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. International Journal of Cancer. 2007 Jun 15;120(12):2656–2664
  36. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. International Journal of Cancer. 2004 Jan 10;108(2):262–268
  37. Verheus M, Peeters PH, Rinaldi S, et al. Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). International Journal of Cancer. 2006 Aug 1;119(3):659–667
  38. Eliassen AH, Tworoger SS, Mantzoros CS, et al. Circulating insulin and c-peptide levels and risk of breast cancer among predominately premenopausal women. Cancer Epidemiology, Biomarkers & Prevention. 2007 Jan;16(1):161–164
  39. Huxley R, nsary-Moghaddam A, Berrington de GA, et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. British Journal of Cancer. 2005 Jun 6;92(11):2076–2083
  40. Friberg E, Orsini N, Mantzoros CS, et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007 Jul;50(7):1365–1374
  41. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. International Journal of Cancer. 2007 Aug 15;121(4):856–862
  42. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. Journal of the National Cancer Institute. 2005 Nov 16;97(22):1679–1687
  43. Mori M, Saitoh S, Takagi S, et al. A Review of Cohort Studies on the Association Between History of Diabetes Mellitus and Occurrence of Cancer. Asian Pacific Journal of Cancer Prevention. 2000;1(4):269–276
  44. Khan AE, Gallo V, Linseisen J, et al. Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition. Haematologica. 2008 Jun;93(6):842–850
  45. Jee SH, Ohrr H, Sull JW, et al. Fasting serum glucose level and cancer risk in Korean men and women. The Journal of the American Medical Association. 2005 Jan 12;293(2):194–202
  46. Stattin P, Bjor O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007 Mar;30(3):561–567
  47. Rapp K, Schroeder J, Klenk J, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia. 2006 May;49(5):945–952
  48. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ (Clinical Research Ed.). 2005 Jun 4;330(7503):1304–1305
  49. Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006 Feb;29(2):254–258
  50. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Research. 2006 Nov 1;66(21):10269–10273
  51. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews. 1995 Feb;16(1):3–34
  52. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nature Reviews. Cancer. 2004 Jul;4(7):505–518
  53. Foti M, Moukil MA, Dudognon P, et al. Insulin and IGF-1 receptor trafficking and signalling. Novartis Foundation Symposium. 2004;262:125–141
  54. Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. The Proceedings of the Nutrition Society. 2001 Feb;60(1):91–106
  55. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocrine Reviews. 1994 Feb;15(1):80–101
  56. Clemmons DR, Underwood LE. Nutritional regulation of IGF-I and IGF binding proteins. Annual Review of Nutrition. 1991;11:393–412
  57. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. European Journal of Endocrinology. 2004 Feb;150(2):161–171
  58. Gram IT, Norat T, Rinaldi S, et al. Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. International Journal of Obesity (2005). 2006 Nov;30(11):1623–1631
  59. Noguchi T. Protein nutrition and insulin-like growth factor system. The British Journal of Nutrition. 2000 Dec;84(Suppl 2):S241–S244
  60. Allen NE, Appleby PN, Davey GK, et al. The associations of diet with serum insulin-like growth factor I and its main binding proteins in 292 women meat-eaters, vegetarians, and vegans. Cancer Epidemiology, Biomarkers & Prevention. 2002 Nov;11(11):1441–1448
  61. Allen NE, Appleby PN, Davey GK, et al. Hormones and diet: low insulin-like growth factor-I but normal bioavailable androgens in vegan men. British Journal of Cancer. 2000 Jul;83(1):95–97
  62. Norat T, Dossus L, Rinaldi S, et al. Diet, serum insulin-like growth factor-I and IGF-binding protein-3 in European women. European Journal of Clinical Nutrition. 2007 Jan;61(1):91–98
  63. Holmes MD, Pollak MN, Willett WC, et al. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiology, Biomarkers & Prevention. 2002 Sep;11(9):852–861
  64. Giovannucci E, Pollak M, Liu Y, et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiology, Biomarkers & Prevention. 2003 Feb;12(2):84–89
  65. Morimoto LM, Newcomb PA, White E, et al. Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: personal and lifestyle factors (United States). Cancer Causes & Control. 2005 Oct;16(8):917–927
  66. Gibney J, Healy ML, Sonksen PH. The growth hormone/insulin-like growth factor-I axis in exercise and sport. Endocrine Reviews. 2007 Oct;28(6):603–624
  67. Leroith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Letters. 2003 Jun 10;195(2):127–137
  68. DiGiovanni J, Bol DK, Wilker E, et al. Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumour promotion. Cancer Research. 2000 Mar 15;60(6):1561–1570
  69. Bol DK, Kiguchi K, Gimenez-Conti I, et al. Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumour formation in transgenic mice. Oncogene. 1997 Apr 10;14(14):1725–1734
  70. Hursting SD, Lavigne JA, Berrigan D, et al. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annual Review of Medicine. 2003;54:131–152
  71. Dunn SE, Kari FW, French J, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumour progression in p53-deficient mice. Cancer Research. 1997 Nov 1;57(21):4667–4672
  72. Hursting SD, Switzer BR, French JE, et al. The growth hormone: insulin-like growth factor 1 axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fischer rats. Cancer Research. 1993 Jun 15;53(12):2750–2757
  73. Wu Y, Cui K, Miyoshi K, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumours. Cancer Research. 2003 Aug 1;63(15):4384–4388
  74. Wu Y, Yakar S, Zhao L, et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Research. 2002 Feb 15;62(4):1030–1035
  75. Ealey KN, Xuan W, Lu S, et al. Colon carcinogenesis in liver-specific IGF-I-deficient (LID) mice. International Journal of Cancer. 2008 Jan 15;122(2):472–476
  76. Stattin P, Rinaldi S, Biessy C, et al. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. Journal of Clinical Oncology. 2004 Aug 1;22(15):3104–3112
  77. Weiss JM, Huang WY, Rinaldi S, et al. IGF-1 and IGFBP-3: risk of prostate cancer among men in the prostate, lung, colorectal and ovarian cancer screening trial. International Journal of Cancer. 2007 Nov 15;121(10):2267–2273
  78. Kaaks R, Lundin E, Rinaldi S, et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes & Control. 2002 May;13(4):307–316
  79. Rinaldi S, Peeters PH, Berrino F, et al. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). Endocrine-Related Cancer. 2006 Jun;13(2):593–605
  80. Schernhammer ES, Holly JM, Hunter DJ, et al. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocrine-Related Cancer. 2006 Jun;13(2):583–592
  81. Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. Journal of the National Cancer Institute. 2000 Oct 4;92(19):1592–1600
  82. Wei EK, Ma J, Pollak MN, et al. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiology, Biomarkers & Prevention. 2005 Apr;14(4):850–855
  83. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004 Apr 24;363(9418):1346–1353
  84. Otani T, Iwasaki M, Sasazuki S, et al. Plasma C-peptide, insulin-like growth factor-I, insulin-like growth factor binding proteins and risk of colorectal cancer in a nested case-control study: the Japan public health center-based prospective study. International Journal of Cancer. 2007 May 1;120(9):2007–2012
  85. Wolpin BM, Michaud DS, Giovannucci EL, et al. Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts. British Journal of Cancer. 2007 Jul 2;97(1):98–104
  86. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Research. 2008 Jan 1;68(1):329–337
  87. Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocrine-Related Cancer. 2006 Jun;13(2):273–278
  88. Baglietto L, English DR, Hopper JL, et al. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiology, Biomarkers & Prevention. 2007 Apr;16(4):763–768
  89. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. Journal of the National Cancer Institute. 2003 Aug 20;95(16):1218–1226
  90. Bezemer ID, Rinaldi S, Dossus L, et al. C-peptide, IGF-I, sex-steroid hormones and adiposity: a cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes & Control. 2005 Jun;16(5):561–572
  91. Poretsky L, Cataldo NA, Rosenwaks Z, et al. The insulin-related ovarian regulatory system in health and disease. Endocrine Reviews. 1999 Aug;20(4):535–582
  92. Kaaks R, Lukanova A, Sommersberg B. Plasma androgens, IGF-1, body size, and prostate cancer risk: a synthetic review. Prostate Cancer and Prostatic Diseases. 2000 Nov;3(3):157–172
  93. Chan MF, Dowsett M, Folkerd E, et al. Usual physical activity and endogenous sex hormones in postmenopausal women: the European prospective investigation into cancer-norfolk population study. Cancer Epidemiology, Biomarkers & Prevention. 2007 May;16(5):900–905
  94. McTiernan A, Wu L, Chen C, et al. Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity (Silver Spring, Md.). 2006 Sep;14(9):1662–1677
  95. Verkasalo PK, Thomas HV, Appleby PN, et al. Circulating levels of sex hormones and their relation to risk factors for breast cancer: a cross-sectional study in 1092 pre- and postmenopausal women (United Kingdom). Cancer Causes & Control. 2001 Jan;12(1):47–59
  96. McTiernan A, Tworoger SS, Ulrich CM, et al. Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. Cancer Research. 2004 Apr 15;64(8):2923–2928
  97. McTiernan A, Tworoger SS, Rajan KB, et al. Effect of exercise on serum androgens in postmenopausal women: a 12-month randomized clinical trial. Cancer Epidemiology, Biomarkers & Prevention. 2004 Jul;13(7):1099–1105
  98. Hawkins VN, Foster-Schubert K, Chubak J, et al. Effect of exercise on serum sex hormones in men: a 12-month randomized clinical trial. Medicine and Science in Sports and Exercise. 2008 Feb;40(2):223–233
  99. Arts CJ, van den BH, Thijssen JH. Effects of dietary fiber on N-nitrosomethylurea-induced mammary tumours and on plasma estrogen levels in rats. Journal of the National Cancer Institute. 1991 Sep 18;83(18):1347–1348
  100. Wayne SJ, Neuhouser ML, Ulrich CM, et-al. Dietary fiber is associated with serum sex hormones and insulin-related peptides in postmenopausal breast cancer survivors. Breast Cancer Research and Treatment, in press.
  101. Monroe KR, Murphy SP, Henderson BE, et al. Dietary fiber intake and endogenous serum hormone levels in naturally postmenopausal Mexican American women: the Multiethnic Cohort Study. Nutrition and Cancer. 2007;58(2):127–135
  102. Rock CL, Flatt SW, Thomson CA, et al. Effects of a high-fiber, low-fat diet intervention on serum concentrations of reproductive steroid hormones in women with a history of breast cancer. Journal of Clinical Oncology. 2004 Jun 15;22(12):2379–2387
  103. Berrino F, Bellati C, Secreto G, et al. Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trial. Cancer Epidemiology, Biomarkers & Prevention. 2001 Jan;10(1):25–33
  104. Kaaks R, Bellati C, Venturelli E, et al. Effects of dietary intervention on IGF-I and IGF-binding proteins, and related alterations in sex steroid metabolism: the Diet and Androgens (DIANA) Randomised Trial. European Journal of Clinical Nutrition. 2003 Sep;57(9):1079–1088
  105. Wang C, Catlin DH, Starcevic B, et al. Low-fat high-fiber diet decreased serum and urine androgens in men. The Journal of Clinical Endocrinology and Metabolism. 2005 Jun;90(6):3550–3559
  106. Dickson RB, Stancel GM. Estrogen receptor-mediated processes in normal and cancer cells. Journal of the National Cancer Institute Monographs. 2000;27:135–145
  107. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. Journal of the National Cancer Institute. 2002 Apr 17;94(8):606–616
  108. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocrine-Related Cancer. 2005 Dec;12(4):1071–1082
  109. Missmer SA, Eliassen AH, Barbieri RL, et al. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. Journal of the National Cancer Institute. 2004 Dec 15;96(24):1856–1865
  110. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). Journal of the National Cancer Institute. 2005 May 18;97(10):755–765
  111. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. Journal of the National Cancer Institute. 2006 Oct 4;98(19):1406–1415
  112. Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. International Journal of Cancer. 2004 Nov 1;112(2):312–318
  113. Kabuto M, Akiba S, Stevens RG, et al. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiology, Biomarkers & Prevention. 2000 Jun;9(6):575–579
  114. Rosenberg CR, Pasternack BS, Shore RE, et al. Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. American Journal of Epidemiology. 1994 Sep 15;140(6):518–525
  115. Thomas HV, Key TJ, Allen DS, et al. A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. British Journal of Cancer. 1997;75(7):1075–1079
  116. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. British Journal of Cancer. 2001 Apr 6;84(7):975–981
  117. Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. International Journal of Cancer. 2004 Jan 20;108(3):425–432
  118. Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocrine-Related Cancer. 2008 Jun;15(2):485–497
  119. Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. The Journal of the American Medical Association. 1995 Dec 27;274(24):1926–1930
  120. Lukanova A, Lundin E, Akhmedkhanov A, et al. Circulating levels of sex steroid hormones and risk of ovarian cancer. International Journal of Cancer. 2003 May 1;104(5):636–642
  121. Rinaldi S, Dossus L, Lukanova A, et al. Endogenous androgens and risk of epithelial ovarian cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiology, Biomarkers & Prevention. 2007 Jan;16(1):23–29
  122. Tworoger SS, Lee IM, Buring JE, et al. Plasma androgen concentrations and risk of incident ovarian cancer. American Journal of Epidemiology. 2008 Jan 15;167(2):211–218
  123. Roddam AW, Allen NE, Appleby P, et al. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Journal of the National Cancer Institute. 2008 Feb 6;100(3):170–183
  124. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: a regulator of inflammation. Best Practice & Research. Clinical Endocrinology & Metabolism. 2005 Dec;19(4):547–566
  125. Hotamisligil GS, Spiegelman BM. Tumour necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994 Nov;43(11):1271–1278
  126. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Reviews. Immunology. 2006 Oct;6(10):772–783
  127. Lago F, Dieguez C, Gomez-Reino J, et al. Adipokines as emerging mediators of immune response and inflammation. Nature Clinical Practice. Rheumatology. 2007 Dec;3(12):716–724
  128. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. The Journal of Clinical Investigation. 2003 Dec;112(12):1785–1788
  129. Schaffler A, Muller-Ladner U, Scholmerich J, et al. Role of adipose tissue as an inflammatory organ in human diseases. Endocrine Reviews. 2006 Aug;27(5):449–467
  130. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. The Journal of Clinical Investigation. 2003 Dec;112(12):1796–1808
  131. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. The Journal of Clinical Investigation. 2003 Dec;112(12):1821–1830
  132. Volanakis JE. Human C-reactive protein: expression, structure, and function. Molecular Immunology. 2001 Aug;38(2–3):189–197
  133. Vozarova B, Weyer C, Hanson K, et al. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obesity Research. 2001 Jul;9(7):414–417
  134. Khaodhiar L, Ling PR, Blackburn GL, et al. Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. JPEN. Journal of Parenteral and Enteral Nutrition. 2004 Nov;28(6):410–415
  135. Himmerich H, Fulda S, Linseisen J, et al. TNF-alpha, soluble TNF receptor and interleukin-6 plasma levels in the general population. European Cytokine Network. 2006 Sep;17(3):196–201
  136. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumour necrosis factor-alpha in human obesity and insulin resistance. The Journal of Clinical Investigation. 1995 May;95(5):2409–2415
  137. Dandona P, Aljada A, Ghanim H, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. The Journal of Clinical Endocrinology and Metabolism. 2004 Oct;89(10):5043–5047
  138. Meier CA, Bobbioni E, Gabay C, et al. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin?. The Journal of Clinical Endocrinology and Metabolism. 2002 Mar;87(3):1184–1188
  139. de FS, Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2002 Mar;317(1–2):1–15
  140. Esposito K, Pontillo A, Di PC, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. The Journal of the American Medical Association. 2003 Apr 9;289(14):1799–1804
  141. Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002 Feb 19;105(7):804–809
  142. Gavrila A, Chan JL, Yiannakouris N, et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. The Journal of Clinical Endocrinology and Metabolism. 2003 Oct;88(10):4823–4831
  143. Im JA, Kim SH, Lee JW, et al. Association between hypoadiponectinemia and cardiovascular risk factors in nonobese healthy adults. Metabolism: Clinical and Experimental. 2006 Nov;55(11):1546–1550
  144. Kotidis EV, Koliakos GG, Baltzopoulos VG, et al. Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment–a prospective study. Obesity Surgery. 2006 Nov;16(11):1425–1432
  145. Manco M, Fernandez-Real JM, Equitani F, et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. The Journal of Clinical Endocrinology and Metabolism. 2007 Feb;92(2):483–490
  146. Matsubara M, Namioka K, Katayose S. Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. European Journal of Endocrinology. 2003 Jun;148(6):657–662
  147. Das UN. Is obesity an inflammatory condition?. Nutrition (Burbank, Los Angeles County, Calif.). 2001 Nov;17(11–12):953–966
  148. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. European Journal of Clinical Investigation. 2002 Jun;32(Suppl 3):24–34
  149. Leroith D. Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. The American Journal of Medicine. 2002 Oct 28;113(Suppl 6A):3S–11S
  150. Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. The Journal of Clinical Investigation. 2002 Sep;110(6):851–860
  151. Havel PJ. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Current Opinion in Lipidology. 2002 Feb;13(1):51–59
  152. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. International Journal of Obesity and Related Metabolic Disorders. 2000 Nov;24(Suppl 4):S23–S27
  153. Kahn BB, Flier JS. Obesity and insulin resistance. The Journal of Clinical Investigation. 2000 Aug;106(4):473–481
  154. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends in Endocrinology and Metabolism: TEM. 2002 Jan;13(1):18–23
  155. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science (New York, N.Y.). 1996 Feb 2;271(5249):665–668
  156. Jager J, Gremeaux T, Cormont M, et al. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology. 2007 Jan;148(1):241–251
  157. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumour necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. The Journal of Biological Chemistry. 2003 Nov 14;278(46):45777–45784
  158. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. The Journal of the American Medical Association. 2001 Jul 18;286(3):327–334
  159. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes. 2005 Dec;54(Suppl 2):S114–S124
  160. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. Journal of Internal Medicine. 2002 Feb;251(2):87–101
  161. Robertson RP, Harmon J, Tran PO, et al. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004 Feb;53(Suppl 1):S119–S124
  162. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocrine Reviews. 2005 May;26(3):439–451
  163. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine. 2002 Nov;8(11):1288–1295
  164. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000 Jun;20(6):1595–1599
  165. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. The Journal of Clinical Endocrinology and Metabolism. 2001 May;86(5):1930–1935
  166. Tergaonkar V. NFkappaB pathway: a good signaling paradigm and therapeutic target. The International Journal of Biochemistry & Cell Biology. 2006;38(10):1647–1653
  167. Karin M. NF-kappaB and cancer: mechanisms and targets. Molecular Carcinogenesis. 2006 Jun;45(6):355–361
  168. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiology, Biomarkers & Prevention. 2005 Oct;14(10):2413–2418
  169. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005 Mar;7(3):211–217
  170. Arango HA, Icely S, Roberts WS, et al. Aspirin effects on endometrial cancer cell growth. Obstetrics and Gynecology. 2001 Mar;97(3):423–427
  171. Gao J, Niwa K, Sun W, et al. Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Science. 2004 Nov;95(11):901–907
  172. Dai Y, Wang WH. Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World Journal of Gastroenterology: WJG. 2006 May 14;12(18):2884–2889
  173. Rayyan Y, Williams J, Rigas B. The role of NSAIDs in the prevention of colon cancer. Cancer Investigation. 2002;20(7–8):1002–1011
  174. Jacobs EJ, Rodriguez C, Mondul AM, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. Journal of the National Cancer Institute. 2005 Jul 6;97(13):975–980
  175. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology (Cambridge, Mass.). 1996 Mar;7(2):203–205
  176. Schildkraut JM, Moorman PG, Halabi S, et al. Analgesic drug use and risk of ovarian cancer. Epidemiology (Cambridge, Mass.). 2006 Jan;17(1):104–107
  177. Moysich KB, Baker JA, Rodabaugh KJ, et al. Regular analgesic use and risk of endometrial cancer. Cancer Epidemiology, Biomarkers & Prevention. 2005 Dec;14(12):2923–2928
  178. Zhang SM, Buring JE, Lee IM, et al. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Annals of Internal Medicine. 2005 Mar 15;142(6):425–432
  179. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. Journal of Clinical Oncology. 2006 Nov 20;24(33):5216–5222
  180. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Research. 2006 Feb 15;66(4):2483–2487
  181. Otani T, Iwasaki M, Sasazuki S, et al. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiology, Biomarkers & Prevention. 2006 Apr;15(4):690–695
  182. Trichopoulos D, Psaltopoulou T, Orfanos P, et al. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiology, Biomarkers & Prevention. 2006 Feb;15(2):381–384
  183. Erlinger TP, Platz EA, Rifai N, et al. C-reactive protein and the risk of incident colorectal cancer. The Journal of the American Medical Association. 2004 Feb 4;291(5):585–590
  184. McSorley MA, Alberg AJ, Allen DS, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstetrics and Gynecology. 2007 Apr;109(4):933–941
  185. Chung YC, Chang YF. Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. European Journal of Gastroenterology & Hepatology. 2003 Apr;15(4):369–373
  186. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. Journal of the National Cancer Institute. 2005 Nov 16;97(22):1688–1694
  187. Ishikawa M, Kitayama J, Kazama S, et al. Plasma adiponectin and gastric cancer. Clinical Cancer Research. 2005 Jan 15;11(2 Pt 1):466–472
  188. Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. The Journal of Clinical Endocrinology and Metabolism. 2004 Mar;89(3):1102–1107
  189. Miyoshi Y, Funahashi T, Kihara S, et al. Association of serum adiponectin levels with breast cancer risk. Clinical Cancer Research. 2003 Nov 15;9(15):5699–5704
  190. Chen DC, Chung YF, Yeh YT, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Letters. 2006 Jun 8;237(1):109–114
  191. Tworoger SS, Eliassen AH, Kelesidis T, et al. Plasma adiponectin concentrations and risk of incident breast cancer. The Journal of Clinical Endocrinology and Metabolism. 2007 Apr;92(4):1510–1516
  192. Dal ML, Augustin LS, Karalis A, et al. Circulating adiponectin and endometrial cancer risk. The Journal of Clinical Endocrinology and Metabolism. 2004 Mar;89(3):1160–1163
  193. Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. The Journal of Clinical Endocrinology and Metabolism. 2003 Mar;88(3):993–997
  194. Soliman PT, Wu D, Tortolero-Luna G, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006 Jun 1;106(11):2376–2381
  195. Cust AE, Kaaks R, Friedenreich C, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. The Journal of Clinical Endocrinology and Metabolism. 2007 Jan;92(1):255–263

PII: S1521-690X(08)00089-4

doi: 10.1016/j.beem.2008.08.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 4 , Pages 551-571 , August 2008

Article Tools